Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, North America, and the Asia Pacific.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.12|
|52 Week High||AU$0.024|
|52 Week Low||AU$0.47|
|1 Month Change||0%|
|3 Month Change||-11.54%|
|1 Year Change||296.55%|
|3 Year Change||-75.53%|
|5 Year Change||-63.49%|
|Change since IPO||-55.77%|
Recent News & Updates
|CPH||AU Pharmaceuticals||AU Market|
Return vs Industry: CPH exceeded the Australian Pharmaceuticals industry which returned 4.9% over the past year.
Return vs Market: CPH exceeded the Australian Market which returned 20.3% over the past year.
Stable Share Price: CPH is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: CPH's weekly volatility has decreased from 21% to 8% over the past year.
About the Company
Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, North America, and the Asia Pacific. The company develops and commercializes therapeutic products; and cultivates and harvests cannabis plants, as well as supplies dried cannabis plant retail products. Its products include anibidiol, a complementary feed product for companion animals; cannaQIX, a nutraceutical product containing hemp oil extract, and vitamins and zinc that reduces stress and supports psychological and nervous functions in humans; and topical and skin care products, which include cannaDOL, a CBD-based topical gel associated with a mixture of cooling and warming essential oils.
Creso Pharma Fundamentals Summary
|CPH fundamental statistics|
Is CPH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CPH income statement (TTM)|
|Cost of Revenue||AU$7.28m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.027|
|Net Profit Margin||-803.27%|
How did CPH perform over the long term?See historical performance and comparison
Is Creso Pharma undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CPH's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CPH's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CPH is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.
PE vs Market: CPH is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CPH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CPH is overvalued based on its PB Ratio (5.2x) compared to the AU Pharmaceuticals industry average (3.5x).
How is Creso Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Creso Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Creso Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CPH is currently unprofitable.
Growing Profit Margin: CPH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CPH is unprofitable, and losses have increased over the past 5 years at a rate of 29.6% per year.
Accelerating Growth: Unable to compare CPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.4%).
Return on Equity
High ROE: CPH has a negative Return on Equity (-120.75%), as it is currently unprofitable.
How is Creso Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: CPH's short term assets (A$16.6M) exceed its short term liabilities (A$1.3M).
Long Term Liabilities: CPH has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: CPH is debt free.
Reducing Debt: CPH had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CPH has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: CPH has less than a year of cash runway if free cash flow continues to reduce at historical rates of 25% each year
What is Creso Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CPH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CPH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CPH's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Creso Pharma has no CEO, or we have no data on them.
Experienced Management: CPH's management team is considered experienced (3 years average tenure).
Experienced Board: CPH's board of directors are considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 74.5%.
Creso Pharma Limited's employee growth, exchange listings and data sources
- Name: Creso Pharma Limited
- Ticker: CPH
- Exchange: ASX
- Founded: 2015
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$138.180m
- Shares outstanding: 1.20b
- Website: https://www.cresopharma.com
- Creso Pharma Limited
- 145 Stirling Highway
- Suite 5 CPC
- Western Australia
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/19 15:54|
|End of Day Share Price||2021/10/19 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.